Combined Effects of Small Apolipoprotein (a) Isoforms and Small, Dense LDL on Coronary Artery Disease Risk

Archives of Medical Research

Volumn 40, Issue 1, 2009, Pages 29-35

  Zeljkovic, Aleksandra ^a   Bogavac Stanojevic, Natasa ^a   Jelic Ivanovic, Zorana ^a   Spasojevic Kalimanovska, Vesna ^a   Vekic, Jelena ^a   Spasic, Slavica ^a  

^a Faculty of Pharmacy   (Serbia)

Author keywords

Apolipoprotein (a); Coronary artery disease; Small dense LDL

Indexed keywords

APOLIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGAR GEL ELECTROPHORESIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE;

APOPROTEIN(A); CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RISK FACTORS;

EID: 57149107816     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2008.10.010     Document Type: Article

References (39)

1. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 59 (1963) 362-382
2. Albers J.J., Kennedy H., and Marcovina S.M. Evidence that Lp(a) contains one molecule of apo(a) and one molecule of apo B: evaluation of amino acid analysis data. J Lipid Res 37 (1996) 192-196
3. Lackner C., Cohen J.C., and Hobbs H.H. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 2 (1993) 933-940
4. van der Hoek Y.Y., Wittekoek M.E., Beisiegel U., Kastelein J.J., and Koschinsky M.L. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably sized isoforms. Hum Mol Genet 2 (1993) 361-366
5. Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmler H.G., and Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80 (1987) 458-465
6. Lackner C., Boerwinkle E., Leffert C.C., Rahmig T., and Hobbs H.H. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 87 (1991) 2153-2161
7. Amemiya H., Arinami T., Kikuchi S., Yamakawa-Kobayashi K., Li L., Fujiwara H., et al. Apolipoprotein(a) and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease. Atherosclerosis 123 (1996) 181-191
8. Rifai N., Ma J., Sacks F.M., Ridker P.M., Hernandez W.J., Stampfer M.J., et al. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. Clin Chem 50 (2004) 1364-1371
9. Berneis K.K., and Krauss R.M. Metabolic origin and clinical significance of LDL heterogeneity. J Lipid Res 43 (2002) 1363-1379
10. Koba S., Hirano T., Kondo T., Shibata M., Suzuki H., Murakami M., et al. Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. Am Heart J 144 (2002) 1026-1035
11. Nakajima K., Hinman J., Pfaffinger D., Edelstein C., and Scanu A.M. Changes in plasma triglyceride levels shift lipoprotein(a) density in parallel with that of LDL independently of apolipoprotein(a) size. Arterioscler Thromb Vasc Biol 21 (2001) 1238-1243
12. Kraft H.G., Köchl S., Menzel H.J., Sandholzer C., and Utermann G. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet 90 (1992) 220-230
13. Scanu A.M. Lp(a) lipoprotein-coping with heterogeneity. N Engl J Med 349 (2003) 2089-2090
14. Reblin T., Hahn K.R., Bethge F., and Greten H. Quantification of lipoprotein(a) and apolipoprotein(a) in plasma and lipoprotein fractions in the hypertriglyceridemic state. Atherosclerosis 145 (1999) 71-79
15. Dangas G., Ambrose J.A., D'Agate D.J., Shao J.H., Chockalingham S., Levine D., et al. Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease. Am J Cardiol 8 (1999) 583-585
16. Zampoulakis J.D., Kyriakousi A.A., Poralis K.A., Karaminas N.T., Palermos I.D., Chimonas E.T., et al. Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes. Clin Cardiol 23 (2000) 895-900
17. Moon J., Kwon H., Kwon S., Yoon S., Kim J., Lee S., et al. Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology 108 (2007) 282-289
18. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
19. Kamboh M.I., Ferrel R.E., and Kottke B.A. Expressed hypervariable polimorphism of apolipoprotein (a). Am J Hum Genet 49 (1991) 1063-1074
20. Rainwater D.L., Andres D.W., Ford A.L., Lowe W.F., Blanche P.J., and Krauss R.M. Production of polyacrylamide gradient gels for the electrophoretic resolution of lipoproteins. J Lipid Res 33 (1992) 1876-1881
21. Zeljkovic A., Spasojevic-Kalimanovska V., Vekic J., Jelic-Ivanovic Z., Topic A., Bogavac-Stanojevic N., et al. Does simultaneous determination of LDL and HDL particle size improve prediction of coronary artery disease risk?. Clin Exp Med 8 (2008) 109-116
22. Vekic J., Topic A., Zeljkovic A., Jelic-Ivanovic Z., and Spasojevic-Kalimanovska V. LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin Biochem 40 (2007) 310-316
23. St-Pierre A.C., Ruel I.L., Cantin B., Dagenais G.R., Bernard P.M., Despres J.P., et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 104 (2001) 2295-2299
24. Bland J.M., and Altman D.G. Transformations, means and confidence intervals. BMJ 312 (1996) 1079
25. Khoury M.J., and Flanders W.D. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls!. Am J Epidemiol 144 (1996) 207-213
26. Hopkins P.N., Wu L.L., Hunt S.C., James B.C., Vincent G.M., and Williams R.R. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 17 (1997) 2783-2792
27. Wang X.L., Cranney G., and Wilcken D.E. Lp(a) and conventional risk profiles predict the severity of coronary stenosis in high-risk hospital-based patients. Aust NZ J Med 30 (2000) 333-338
28. Marcovina S.M., and Koschinsky M.L. A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment?. Semin Vasc Med 2 (2002) 335-344
29. Gaw A., Brown E.A., and Ford I. Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations evidence for a threshold effect. Arterioscler Thromb Vasc Biol 18 (1998) 1870-1876
30. Rainwater D.L., Ludwig M.J., Haffner S.M., and VandeBerg J.L. Lipid and lipoprotein factors associated with variation in Lp(a) density. Arterioscler Thromb Vasc Biol 15 (1995) 313-319
31. Sacks F.M., and Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 88 (2003) 4525-4532
32. Carr M.C., Ayyobi A.F., Murdoch S.J., Deeb S.S., and Brunzell J.D. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol 22 (2002) 667-673
33. Austin M.A., and Hokanson J.E. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease. Med Clin North Am 78 (1994) 99-115
34. Kostner K.M., and Kostner G.M. Therapy of hyper-Lp(a). HEP 170 (2005) 519-536
35. Kronenberg F., Lingenhel A., Lhotta K., Rantner B., Kronenberg M., Konig P., et al. Lipoprotein(a)-and low-density lipoprotein-derived cholesterol in nephritic syndrome: impact on lipid-lowering therapy?. Kidney Int 66 (2004) 348-354
36. Miller M. Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc 78 (2003) 735-742
37. Bays H.E., and McGovern M.E. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 6 (2003) 179-188
38. Guyton J.R., and Capuzzi D.M. Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 82 (1998) 82U-84U
39. Cignarella A., Bellosta S., Corsini A., and Bolego C. Hypolipidemic therapy for the metabolic syndrome. Pharmacol Res 53 (2006) 492-500